Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results

Posted by Brenda Bartman on Nov 9th, 2026

Editas Medicine (NASDAQ:EDIT – Get Free Report) announced its earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04, FiscalAI reports. The company had revenue of $10.37 million during the quarter, compared to analyst estimates of $4.54 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%.

Editas Medicine Price Performance

Shares of EDIT stock traded up $0.18 during mid-day trading on Monday, hitting $2.75. The stock had a trading volume of 3,718,434 shares, compared to its average volume of 2,232,867. Editas Medicine has a fifty-two week low of $1.66 and a fifty-two week high of $3.94. The firm has a market cap of $422.35 million, a PE ratio of -3.67 and a beta of 2.08. The company’s 50-day simple moving average is $2.70 and its 200-day simple moving average is $2.69.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EDIT. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Guggenheim upgraded shares of Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Wednesday, September 23rd. Wells Fargo & Company upgraded shares of Editas Medicine from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $4.00 to $6.00 in a research note on Thursday, October 8th. Weiss Ratings raised Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, LADENBURG THALM/SH SH started coverage on Editas Medicine in a research report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Editas Medicine currently has an average rating of “Moderate Buy” and an average price target of $5.83.

Check Out Our Latest Analysis on Editas Medicine

Key Headlines Impacting Editas Medicine

Here are the key news stories impacting Editas Medicine this week:

Positive Sentiment: For Q3 2026, Editas reported a loss of $0.15 per share, narrower than analyst expectations of $0.19–$0.21 and the $0.28 loss a year earlier. Revenue of $10.37 million also substantially exceeded the $4.54 million consensus estimate. EDITAS MEDICINE, INC. Q3 Loss Decreases
Positive Sentiment: Editas received Australian ethics approval to begin its Phase 1/2 Strive study of EDIT-401 for hyperlipidemia, with first dosing targeted for 2026. Preclinical data showed at least 90% LDL-C reduction maintained over 10 months, supporting the program’s potential. Third-quarter results and business updates
Positive Sentiment: A second IND/CTA for the CD70 HD Allo CAR T program was accepted under Editas’s collaboration with Bristol Myers Squibb, triggering a milestone payment. Editas said its cash runway extends into the second half of 2028. Third-quarter results and business updates
Negative Sentiment: Editas continues to post quarterly losses; further progress depends on clinical development and future milestones, so the strong results do not remove the risks of a clinical-stage biotech company.

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines using CRISPR-based gene-editing technologies. The company’s research platforms include CRISPR/Cas9 and CRISPR/Cas12a, which are designed to make precise changes to DNA and potentially treat diseases caused by genetic abnormalities.

Editas Medicine’s lead investigational program is reni-cel, formerly known as EDIT-301. Reni-cel is an ex vivo gene-editing therapy intended to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood-forming stem cells before they are returned to the body.